First 10 runs free
    First 10 runs free

    Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation

    Resolved · regulation · Occurred · Assessed · 2 sources

    This assessment is dated 2026-09-28. Check what remains unresolved below before relying on it.

    Which companies' revenue or costs change?

    Pipeline portfolio rationalization protects LLY commercial R&D spending while increasing commercial reliance on existing frontline Mounjaro and Zepbound franchises.

    QuestionWhat the evidence establishes
    What was reported?Reported factEli Lilly discontinued the clinical development of an experimental GLP-1 obesity candidate after it failed to meet internal efficacy benchmarks.
    What else was confirmed?Reported factGLP-1 franchise products, including Mounjaro, Zepbound, and Foundayo, account for over 65% of total Eli Lilly corporate revenue.
    Does the valuation support acting?Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06.
    What would change the assessment?UnknownNext-Gen Oral Obesity Phase II Data Readouts — Clinical efficacy and weight loss percentage updates for secondary oral GLP-1 pipeline assets.

    What would this event cost your holdings?

    Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.

    Test this event against my holdings

    Reported facts

    • · Eli Lilly discontinued the clinical development of an experimental GLP-1 obesity candidate after it failed to meet internal efficacy benchmarks.
    • · GLP-1 franchise products, including Mounjaro, Zepbound, and Foundayo, account for over 65% of total Eli Lilly corporate revenue.
    • · Wall Street consensus holds a $1,325 average price target on LLY shares as the global GLP-1 pharmaceutical market expands.

    Public research record

    Research framework · page evidence

    Completed event assessment

    pipeline attrition offset by frontline GLP-1 revenue concentration

    TypeClaimScope
    AssumptionEli Lilly discontinued the clinical development of an experimental GLP-1 obesity candidate after it failed to meet internal efficacy benchmarks.2026-09-28
    Interpretationpipeline attrition offset by frontline GLP-1 revenue concentrationLLY
    Countercase, invalidators, and sources
    Countercase

    Commercial supply expansions for Zepbound and Mounjaro drive top-line upside, exceeding R&D pipeline attrition.

    What would change the view
    • · Next-Gen Oral Obesity Phase II Data Readouts — Clinical efficacy and weight loss percentage updates for secondary oral GLP-1 pipeline assets.
    • Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become · 2026-09-26

    Get the next source update

    One email when the underlying evidence changes. No daily digest.

    What remains unresolved

    Base path
    Lilly maintains GLP-1 market share lead while advancing next-phase oral obesity candidates.
    Adverse path
    Pipeline candidate failures increase mid-term vulnerability to competitive pricing from peer entrants.
    Supportive path
    Commercial supply expansions for Zepbound and Mounjaro drive top-line upside, exceeding R&D pipeline attrition.
    • · Next-Gen Oral Obesity Phase II Data Readouts — Clinical efficacy and weight loss percentage updates for secondary oral GLP-1 pipeline assets.this week

    Evidence

    • Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become2026-09-26

      “Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue.”

      Supports: Eli Lilly discontinued development of a GLP-1 weight-loss drug; GLP-1 drugs account for over 65% of revenue.